Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Revenio’s press conference on the Visionix acquisition

By Inderes4/13/2026, 11:00 AM
Revenio Group
Investor events

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Jouni Toijala
00:00 - 21:23

Good afternoon from sunny Helsinki and welcome to the webcast, everyone behind the line and also here in Sonoma. My name is Jouni Toijala, and I'm the CEO of Revenio, excited to welcome everyone here in the audience and also on the webcast. So this is a significant day for us as a Revenio and also significant day for Visionix. Visionix. So we are going to make history today. The name of the game today is for me to first go through. The logic why we decided to join forces with Visionix. Robin is going to go through the transaction details. One of the most interesting parts is to actually get Marc from Visionix. So President and CEO in the interview together with Charles from Caravelle and also Arne Boye Nielsen, the Chairman of the Board for Revenio. We have been having many, many discussions, I would say even countless discussions, regarding what would be the dream case, a match made in heaven for Revenio to join forces with. I can see many familiar faces here from the analysts. Also. We have had an extremely large amount of investor roadshows, and what we have been answering with Robin is that it would be great for the group in the long term to have an extremely complementary product portfolio, expand our $1 billion market in ophthalmic diagnostic devices to the new segments where we are not currently playing. Then, if we achieve scale with the product portfolio, we are going to achieve scale in the channel to provide a better package in terms of products, also for our distributors. And then of course, the most important part as well is our existing and new shareholders. So we are really able to accelerate the growth. So really happy to announce today that we have now signed the deal with Visionix to join forces. We are going to end up in a totally different league. Sales are going to be roughly 250 million, with EBITDA at 50 million. And the enterprise value of the deal is 290 million. 250 million. Robin is going to go through the details in more detail, but we are going to finance the deal with cash, Revenio shares, debt financing, and a Vendor loan. But Robin is going to come back to this one later. I'm sure we may have slightly disrupted analyst schedules today. So thank you all for coming. Coming here at Sonoma face to face, and I'm sure quite many of you have questions. After reading the news. So you have most probably been looking into Visionix. What Visionix is. It is about the company founded by Marc. So, really happy to have Marc on the stage. Later. He is going to tell the story. And then, in terms of sales. So, a bit bigger. Than Revenio, it has 140 million in sales, an EBITDA level of roughly 16 to 17 million, and five R&D centers across the globe. And then from the sales perspective, this is a really good match for Revenio, as you can see. We have roughly 50% of the revenue coming from the USA, then roughly 30% from Europe, Middle East, Africa, Latam, and Canada, and the remaining part from the APAC. So this is nicely going to balance our combined company in the long run, because a big part of the Visionix revenue is coming from the EMEA region. Then also, we. An extremely good thing is that Visionix also has direct channels, with part of its business coming from the OEM side, and through a U.S. distributor network as well. And from the offering point of view, we are really expanding the portfolio. So we are going to get the comprehensive, extremely high-quality OCT device package. So not only the one device, but the portfolio of devices at the OCT side. Then the Multimodal devices, Refraction systems, Edging & Mounting. And then on the software side, we are going to get the data management platform together with the telehealth, which is picking up really nicely at the Visionix end. We have one product only, which is overlapping, and that's the VX110 Fundus imaging device. But from the product portfolio. Perfect. Perfect match. And if we look at the combined company, so roughly 250 million in revenue and 40 million EBITDA level. We start to be one of the biggest players now on the ophthalmic diagnostic device side. And what's extremely important on this one is that we are expanding the addressable market from 1 billion to 2.5 billion. From 1 billion to 2.5 billion. The biggest part of that is the OCT. Then we get the refractometer, slit lamps, and then the multimodal devices. And if you go back to the earlier discussions, whether they are our earnings calls or AGM or investor roadshows. So we have been saying that the market where we currently operate grows roughly 3 to 4%. So, Fundus imaging grows 3 to 4%, Refractometers 2 to 3%, and Tonometers ballpark the same. Even 1 to 2%. So this now gives us room as a combined company to expand the addressable market from 1 billion to 2.5 billion, including the OCT segment. That's the fastest growing segment as we speak. So a bit after 5%, and then the Multimodal devices are even growing faster. So this is extremely good news for all of us. Then, as we have emphasized, this truly accelerates our growth and value creation. So it's a total step change. Regarding the speed to achieve more growth and value creation, there are three key topics here. So the first one is the complementary product portfolio from the device side and also from the software side. Then I mentioned already that we are increasing the accessible market from 1 billion to 2.5 billion, getting immediate access to the OCT devices, which I think everybody has been missing. And then, the synergies are going to be extremely good. So we are also targeting 20 million EBITDA synergies, which are coming by increasing top line. And then also from the cost side, I'm going to cover these three topics now. True. And I think this best illustrates the product portfolio. So we have been extremely strong on Tonometers. Also, on micro-perimetry, it is a bit more challenging in the Perimetry sector than in the Fundus imaging sector. Extremely strong; there is still room to grow organically, as everybody knows and understands. However, if you now look at the portfolio. So we are going to get a comprehensive portfolio by joining forces with Visionix. We are going to get the OCT devices. So that's a significant fast-growing 700 million accessible market segment. Then we are going to get the Multimodal devices, Refraction systems, and also the Edging & Mounting part. And then the big and extremely important topic is also the already fully operational and sellable telehealth solution, which is the Nexus platform. If we switch the lens a bit and look at this from the optical retail or optometry customer journey point of view. So, as a standalone Revenio, we have never been. So we have had specific products at various points in the journey. So we have had the products in pre-test screening sites, like the Tonometers, and nothing from the refractive side. And then on the diagnostic side. And then of course, nothing on the finishing and dispensing side. But now by joining forces with Visionix, we are actually able to cover the whole end-to-end journey. We address what the patient is going through and truly provide excellent and high-quality diagnostic devices for that, including the software. Another angle or lens to look at this is to look at the different diseases. So we have been strong in Glaucoma and retinal diseases. What we have been missing is the OCT. Now, by combining forces with Visionix, we have it. We haven't been present on Corneal issues. We have not been on the dry eye side, nor on the refractive side. Now we have it by combining the forces. And this is great news. Then the customer segments. So if we think the customer segments where we have been operating. So we have been constantly saying that Revenio as a standalone, 55-60% comes from optometry, then we are reasonably strong in ophthalmology, though we have been missing in certain areas on the ophthalmology side. Regarding the structure. So how to diagnose the structural changes of the retina? We have been missing the OCT. Now we have it ready to sell in all eye care. Their products are extremely good and high-quality. Then for the Optometry segment, we will achieve expansion regarding refraction. And then we haven't been too strong on fully-fledged optical retail. Now we have covered the whole customer journey. And then of course, in addition to that, we have always been in home care settings and other healthcare clinics. And then Maya for pharma and research. Let's wrap this one up. I think this is one of the most important topics. I'm sorry if I'm repeating this one. So we used to be in a 1 billion accessible market with Tonometers, with Fundus imaging, with the Perimetry. Now, that is going to increase from 1 billion to 2.5 billion, incorporating OCT and multimodal slit lamps. Refractometers. This is going to be now the path for us to grow for years to come. So, if we had been only a standalone company, focusing solely on this 1 billion part and coming back to all the earnings calls, AGMs, investor roadshows, or analyst calls, we have been saying that we can grow. And then there has been the discussion and question that what would be the dream package? Dream package is now here. So wider portfolio moving from 1 billion to 2.55 billion in terms of the addressable market. We are able to scale the channel. Get the benefits. Also for customers. So this is really good. This is really good news. And then, if we're really starting to look forward. So we haven't yet fully started the work on this front. But we have been many times saying that we as Revenio, as a standalone, have been constantly investing roughly 10% in R&D, and the Visionix team has been doing more or less the same, and we are going to have extremely compelling products coming out for every segment. It's the same for Visionix. And then if you start really to look the long term, combining OCT with true color confocal, Tonometers, and Multimodal devices, incorporating true color into the Multimodal devices, etc. . So we have a huge trust that we are really able to create new innovations in years to come, but together with the Visionix team. Then value creation. So, two main levers for the synergies and value creation. First one is the commercial part. What to do together to fast-track the top line. And then we have operational levers. And based on our current estimates, roughly 70% of synergies we are able to realize by the end of 2027. And there are upsides on this one, whether it relates to bringing new solutions into the market, or optimizing the assembly. So those things are to be studied in the long run. But let's start with route to market opportunities and the channel optimization. This is excellent news for our distributors. It's excellent news for the direct sales force in the USA. We all go direct in the USA. Now we have a comprehensive portfolio. It's a way wider than before. It's a clear benefit. Then also for our distributors. This is a great opportunity now to plan together how in the long run we do business together, because again, we have a much wider product portfolio. So, really good news then from a cross-upselling perspective. Now, as a combined company, we are actually able to go to new segments. So this is good. So we have a really good, really competitive joint portfolio. As an example, if we go for Spain, Visionix is already distributing our products in Spain. Extremely good. Good traction on the OCT combined with the advanced ultra-wide field imaging. So there are a lot of opportunities in the short term and in the long term to increase sales as a combined company. It's game-changing. It's a game-changing combination. So think about the USA as an example. So, we start to be one of the major players in the USA, with sales expected to be roughly 100 to 110 million USD. This deal also is going to reduce the US risk. So if our US revenue is now 50%, in the long run, it will constitute roughly one-third of the total revenue, or even slightly more than one-third. There's other extremely good countries. Germany, UK, Australia, France, Spain, Italy. And then of course, all the other regions and countries then contributing to the 20% and 26%. Then, from a scale benefits perspective, cost savings constitute the synergies. The main savings from an operating expenses perspective will come from integrating and optimizing the systems. RTI systems, etc. . And then we really start to have volumes on the assembly manufacturing side as well. As everybody knows. So we are not manufacturing anything. Then if we go for Visionix. So they have their own assembly lines. When we start to combine the two companies. So I'm sure we are able to get lots of benefits regarding the joint purchasing, joint supply chain management, etc. . So, this is going to be a big part of the synergies going forward. Before I let Robin to go through the transaction details. So let's wrap up the value creation journey. 2026-2027 at the time for quick wins and mobilizing the team. As I said, we are able to harness 70% of the synergies in the next 18 months. So, if we are more or less finished with the first half, we are going to combine the organization, processes, and systems. So the plan is that we are targeting to close the deal. End of May. We have a plan to have new teams and a clear organization in place right from day one. We hit the ground running in order to harness the synergies right away starting from the second half. And then we also start developing the plan for the long-term strategic synergies. So we are going to have a Capital Markets Day in October-November time frame. We are going to go through the corporate strategy. We are going to refresh the product portfolio and product strategy, and that will be communicated then towards the October and November timeframe. Then. By 2028-2029, we are sure that we are in extremely good shape. What comes to the synergy level? We continue development of new innovative products and solutions. And then we start discussing, of course, before that, how we should optimize the whole assembly line, how the products are going to be manufactured. And I think everybody, of course, is hopefully realizing here that we are really targeting a 25% EBITDA margin by 2028-2029. So the Visionix team has already been working a lot now to improve profitability, and that work is going to continue. And I'm sure that that is what we are able to do. And then that brings us to beyond 2030. And so the plan is to continue to grow. Otherwise it would be a bit more difficult. So if you only had a 1 billion accessible market, now we have one 2.5 times larger. We have an extremely good competitive product portfolio able to provide turnkey solutions for optical retail and optometry, and there will be new and interesting innovations on the product side already now for us. For Visionix. And then in the combination. And really, the plan is to get the profitability in the long run into the level where Revenio standalone is. And we are committed to grow at 3x faster than the market as part of this journey. And now we are going to focus on getting everything ready, planning the integration, which of course is going to be a lot of work, but we have Marc here to support us and all the other team members. So we will be successful in that. So we are going to focus now on the business continuity and building up and continuing the integration work. But with these words, Robin.

Robin Pulkkinen
21:29 - 31:10

Thank you. My name is Robin Pulkkinen. I'm the group CFO for Revenio. Let's go through a little bit how we're going to make this all work out. You probably have read some of these terms already in the releases today. But the enterprise value is 290 million, and 250 million of that is payable to the sellers. And the remaining 40 million is used for repaying current debt, net working capital and other adjustments of the transaction. Basically, 22.3% of the purchase price is being paid with the Revenio shares, new shares that are being issued. The price for which they're being allocated at is 22.4%, which is roughly 14% higher than the closing price on Friday. The remaining 77.7% is being paid in cash. We've agreed with Nordea on a term loan facility for 130 million. Basically, its maturity is four plus one years, with monthly payments of 1 million, payable every six months and tied to the six-month Euribor. Euribor interest and the margins are actually something similar that many would be happy to pay for a house loan. So we're talking about well below 1%, closer to half percent margins on the interest. In addition, we have a Bridge-to-equity facility for 80 million. The idea here is for this to be repaid with the proceeds of the rights issue done in the fall this year. It basically has a six-plus-six-month maturity for the bridge loan. Then, of course, we have cash in hand, as Revenio has always been a very strong cash-generating company. We also have the cash for the target, Visionix, available. And we've also negotiated a 10 million revolving credit limit that is available for us to use if needed. And then finally, we've agreed with the sellers that roughly 10%, a little bit below, of the cash portion is being paid. There is an interest-free Vendor Loan payable 12 months from the closing of the transaction. The AGM was cancelled this morning. The original annual general meeting was supposed to be held on Wednesday this week. The cancellation was because there are no new items we need to bring on the agenda for the new meeting. We're going to be sending out the invitation. This week, and probably the new AGM will be held sometime mid-May. Basically, for completing the transaction, the Board of Directors will be proposing that the AGM approves the share issue of roughly 2.5 million new shares to the sellers. In addition, we need to get the authorization for arranging the rights issue post-closing in the fall of this year. The rights issue has been fully underwritten by Nordea. So, we have fully committed financing available for the transaction. In addition, we will be making a different board proposal for the board members than we had in the original invitation. So, the board proposal will now include the five people from the original invitation, along with three new members. We'll have Charles Vilgrain who's here today. You'll see him in a few moments in the discussion panel. We have Marc Abitbol, the CEO and founder of Visionix, and also Nicklas Hansen, the chief investment officer of William Demant Invest. We've received an irrevocable undertaking from Demant Invest owing roughly 24.5% of our shares to vote in favor of the board proposal in the AGM. After the transaction closes, this is it. Here's how the cap table will look. The Visionix sellers will roughly hold 8.5% of the shares. Basically, there are a couple of people involved. It will be split up. Caravelle is the largest single owner among those sellers receiving shares. And then the post-completion rights issue, we've engaged with Nordea as the global coordinator and underwriter for the rights issue targeting to be arranged in the second half this year. So, we also have commitments regarding the rights issue. William Demant Invest and the sellers, after receiving the shares of the purchase price consideration, have both irrevocably committed to subscribe pro rata for the shares in the rights issue. And then that's basically 31% of the shares outstanding after completion of the transaction. The remaining 69% is underwritten by Nordea. And of course, the proceeds are being used to repay the bridge loan we have in the balance sheet. Looking at the combined numbers. There are a few things that need to be taken into account. You already saw how the numbers would have looked last year if we combined them. Net sales 153 million, adjusted EBITDA 48 million. And it's important to note that the purchase price allocation and related depreciation and amortization are not included here. So those will be published as part of our Q2 numbers that are coming out after summer. I won't be speculating what that might be looking like. But that work is ongoing. And then, on the lower part of the graph, you can see the more the balance sheet items. So the combined unaudited numbers have some adjustments. So the total assets we've added 142 million to that. Basically, it's the difference between the net assets of Visionix and the equity value paid for the acquisition. We've eliminated the Visionix equity and added the 55.7 million share issue to the sellers, to the combined equity, and on the liabilities. We've assumed refinancing of the new financial facilities in place. So if you look at after closing, the net debt to adjusted EBITDA ratio is 4.4x, and the equity ratio is above 35%. Those are expected to significantly improve after the rights issue has been completed. So after the rights issue, we expect the net debt to adjusted EBITDA to be around or below 2.5 and the equity ratio to increase above 50%. And going forward, the group is expected to be a very strong cash generator. So these numbers are expected to improve as we move forward. Visionix will be integrated into the Revenio structure. The combined group will operate under Revenio governance model and reporting framework. So even after closing you'll find us in Nasdaq with the same ticker REG1V. So no change there from an investor point of view. We're looking to leverage the best of both companies. That also goes to a balanced leadership participation. The leadership team will have some changes. As part of this transaction, the new leadership team will be announced. Then, together with the closing timeframe, sometime later during this Q2. So we withdrew our guidance. I guess that's not a surprise to anybody at this stage. We'll be giving out the new guidance after the completion of the transaction. And the one-off cost. So, in order to achieve the synergies we're trying to get from this transaction, there will be one-off costs. Basically, our estimate currently is roughly 20 million, and 30% of that is IT-related, which will be capitalized for a big part. But also there are costs for organizational restructuring, rebranding, marketing, project management, and other costs as well. Those are expected to take place as Jouni expects 70% of the synergies to be realized within the next 18 months. The costs are also expected to take place mostly in the next 18 months, and the AGM is scheduled for sometime in mid-May. Invitation being sent out this week. Completion by the end of Q2. Hopefully a bit sooner than end of June, and then the post-completion rights issue after the summer. So we need, of course, fresh numbers, Q2 reported numbers before we can go out. So most likely, we are looking at an early September-October timeframe. And then can I invite Marc Abitbol, the CEO and founder of Visionix, on stage? Also Arne Boye Nielsen, the chair of the board of Revenio, and Charles Vilgrain, the managing partner for Caravelle Capital.

Arne Boye Nielsen
31:11 - 31:12

Thank you.

Jouni Toijala
31:16 - 31:18

Welcome, gentlemen.

Arne Boye Nielsen
31:19 - 31:19

Thank you.

Jouni Toijala
31:20 - 32:34

Great to have you here. We jump in. We drop in. But now the. Now the situation is different. So we are going to have a couple of topics for today's discussion with the gentlemen. So we are going to start with the strategic rationale and the combined company governance. Then we are going to cover the strategic fit plus the value creation as one theme. And then of course, the interesting part is the integration and the oversight of the integration. And then we have a Joker question at the end. So we wait. We wait for that one. But the first one goes for you. From the Revenio board and shareholder perspective, what makes this acquisition strategically different compared to the other options? What have you been looking for? And how do you see this one playing out? What are the long-term strategic opportunities for the combined company?

Arne Boye Nielsen
32:35 - 34:13

I think it's not a secret that for some time we have been looking at the opportunities for expanding, partly because we needed a broader product program, but also to get a stronger distribution. And this is what I would see as a quite perfect marriage because we are getting a much better, broader product program. We are getting into the OCT business that we can utilize to cross-sell some of the other products. And by that, we can get back on. Not get back on a growth track, but to continue to grow. But what really gives me a good feeling is that over the last month or year, we have spent quite some time together, and also some people in the organization. And I really have a good feeling of the match between the culture and the people. It's very much the same way we are. We are thinking. So. So I think that that is the key. If we didn't have this people match between us and we didn't have the commitment from the sellers—not just taking all the money on the table and leaving the room, but actually that you reinvest in the company and that you also will participate partly on the board, partly in the whole integration of the company—is very, very important. And I think that's important for the future success of this whole joint undertaking that we have to go through, but that we are going through.

Jouni Toijala
34:13 - 36:48

Thank you, thank you. Ana. And perhaps the continuation question, which goes for Charles. So it has been clear since the beginning when talking with Marc, when talking with you, Charles, that you are not just selling as a Visionix shareholder. The shares are out, but you are committed to the longer term journey. So can you explain that logic for us also? I think you are going to subscribe to the shares at a price higher than today's trading price. And so, can you go through the logic, because for me, it's great to hear that as Visionix shareholders, you are staying invested and committed to the long-term growth and opportunities for the company. Thank you very much. For sure. First of all, I represent Caravelle. Caravelle is a French family-owned industrial investor. And we have permanent capital. And we can remain shareholders as long as we believe we're relevant for the company we invest in. As Robin earlier told you, we're not just exiting. We're keeping a 25% exposure. We're buying the Revenio shares at €22.4. So with a slight premium compared to today's price, which will make us the second largest shareholder of the combined group. And we're doing this because we're very confident in the fact that joining forces, as you earlier described, between Revenio and Visionix, will be able to make the leading turnkey solution provider in the global eye care market. And this is what really enthuses us and why we want to remain shareholders in this group. Thank you. Thank you Charles. So Ana, are you able to explain the logic a bit? So Ana, are you able to open the logic? So, William Demant Invest, our biggest shareholder, almost owning roughly 20-25% of shares, is also committed in the long run. So, from all shareholders' perspective, are you able to open that one a bit?

Arne Boye Nielsen
36:49 - 37:23

Of course, we do this investment, this acquisition we do to create value for all shareholders. And we do it because we feel with this acquisition, we are much better prepared to continue the future growth of the company, and we are better prepared to continue to improve the margins as well. I think for all shareholders, this will hopefully mean that we will grow the value of the company in the coming years. And I think that is, at the end of the day, the agenda we have: to create value for the shareholders.

Jouni Toijala
37:24 - 38:38

I fully agree on that one. But Mark, the next one goes for you. So I think that we have had countless discussion days, even nights every now and then, and since the beginning when we started this journey. So it has been quite the journey, like twenty-year-olds or kind of teenagers or so for us. And then we have been wondering what the parents are thinking, but luckily the parents have been positive because the long-term value creation logic is so clear. But Mark. So we have been sharing the same beliefs and principles regarding the joining of forces. So are you able to talk that one through from your perspective? Because Visionix is your creation. It's your baby. It has been yours for 30 years. It's still going to be yours because you are going to stay on the journey. But we have had some pretty sentimental moments, even every now and then, on this one.

Dr. Marc Abitbol
38:39 - 41:53

Let me go back to the first thing you mentioned. I think what was the trigger of it is when we met and felt that we share the same DNA and some values. And there was not a feeling that one company wants to absorb the other. I was very impressed by the way you describe how you want to build a leadership that is balanced. You want to look at the talent within the company and you want to leverage on everything which is on the table. And I've been very impressed by how humbly you came to this discussion. You could come as an acquirer. No, you didn't come with this one. And I think this is fundamental to the success of the second level, which is, what are the fundamentals of these two companies? The fundamental is that there are complementary products, like Jouni described very nicely. And I think, complementarity in product and complementarity in go to market. That means we are creating a product range which is almost unmatched in our market. So that will put on the market, from a competitive point of view, something unique. There is nobody who is going to have the capability to merge ultra wide field with OCT. No. One. And I can list in terms of product and technology and roadmap. The strong advantage we are going to bring to the market. This is number one. Number two, in go-to-market. We are creating in the US the biggest diagnostic presence in the ophthalmic US market. The US market is the biggest ophthalmic market. And we all know that critical mass means in the US. And by this presence we are going to take more market share. We are going to have closer presence to our customers, etc. The mirror of this is in Europe, and our direct presence there, combined with the product range integrated into our direct sales channels, represents a second, extremely important factor for gross margin, as it enables us to capitalize on profit that would otherwise go to distributors, now retained within our direct sales channel from product to market. We are combining something which is unique in this market and for me it's like a bit emotional. Okay. 30 years ago, Visionix was four people in a small caravan. Today, it has almost 600 people. And as I say, I don't want to look at how nice was the past. And I want to look how nice it's going to be in the future. It's beautiful how we are going to be successful. For me. This will be the accomplishment of the past through the success we are going to have. And like Jouni says, not only reinvesting part of it in the combined group, but I'm going to be active together under the supervision of Arne in the board. I'll be there in integration, in technology, to bring the knowledge and the experience and the contacts I have built in this market during 30 years.

Jouni Toijala
41:54 - 42:42

Thank you, Marc. And you stole a couple of my questions regarding the strategic fit and value creation. So thank you for that. I'll skip those ones. But let's move to the integration and the overall oversight. So you, Marc, partly touched upon this. So you are committed to stay on the board in terms of reinvesting into the shares. Then also you are going to help the operational team in an integration. You are going to be part of the board, etc. . So, where or how do you see yourself now after the closing? So where do you see your role evolving?

Dr. Marc Abitbol
42:43 - 44:01

So first of all, I think when two companies like that merge and two very charismatic people like Jouni and myself are together, it is important that they will. One recognizes leadership, and for the combined group, it is Jouni. On the other hand, there is knowledge. And as I say, for me, the success of my past 30 years will yield a strong integration success. And discussing with Arne, we said, where I can help a lot is from the board looking at the integration. The execution of the integration is of course under Jouni, but looking at recommendations, bringing experience, and so on. and helping shape this integration through the knowledge of the company and our customers. This will reflect strong confidence in our customers and employees that we are truly joining forces, because Jouni, as the executive and trusted leader of the company, and I, under the leadership of the board, are going to work together to bring this experience from each side, and this represents an optimal partnership. I have never had such an experience. So I am excited, convinced that we are going right to the target.

Jouni Toijala
44:04 - 44:04

Thank you Marc.

Dr. Marc Abitbol
44:04 - 44:06

I hope I didn't take another question.

Unknown 1
44:06 - 44:08

No, no, no, not this time. Not this.

Jouni Toijala
44:08 - 44:58

Perhaps the question was better for Arne, but hey, regarding the integration, especially the integration oversight. And this goes to you, Jouni. We have set a couple of targets and aims for long-term growth, like 3x faster than the market. Then, by 2029, achieving profitability at the 25.5% EBITDA level. But if you look at what we are trying to achieve on the integration perspective. So, beyond the financial parts as well. How would the successful integration look for you?

Arne Boye Nielsen
44:58 - 46:28

But of course, we are doing this because we believe that we can get two plus two to be more than four. And the only way we can get two plus two to be more than four. That is to approach this in a very, very structured way. And the fantastic thing, regarding the culture and the meetings we have had so far, is that it's not like one company is acquiring the other. It has really been fantastic open discussions where we are learning from each other. We look at what works best. What did you do great or what do you do great in Visionix? What do we do great at Revenio? Where can we learn from each other? And so on. And it is to find the best practices from both parts of the company. And then we're really in a very structured way. Make sure that we benefit from this learning and implement it across the whole organization. So, in some years from now. So with some years from now, we will have one organization that is running the same way and to win more business. Help more customers in the market. I think that is at the end of the day. But of course, we can also see that we have committed to a minimum of €20 million in synergies. The only way we can harvest €20 million in synergies in the market. That is hard, dedicated work. But we have looked. It's not just something we have spent five minutes at looking at. Where is it? We can find €20 million. There's a very good plan behind those €20 million.

Jouni Toijala
46:29 - 48:52

Thank you. Ana. I think we are starting to finalize this wonderful discussion with the last Joker question. So what excites you most professionally and personally? About the next chapter. We are now starting to build together. First, we start from Charles again and we finish up with Marc. It's a good question. Difficult one, I think 2 or 3 things. I think that the Visionix mission has always been to improve eye care through technology and accessibility. It's very important. It has always been important for Marc and us. I think that this combined Visionix will provide even better solutions to the eye care professionals to empower them with intuitive, reliable, integrated solutions and those solutions to transform the patient care journey with the new exams that will be more efficient, accurate and accessible. As we said. So this is very important from this mission standpoint of view. But as Caravelle, we're truly excited to see Visionix joining forces with a business of Revenio's caliber. Definitely, the combined entity will now have, as Marc earlier said, the resources, the critical mass to address the new challenges. And definitely, those two groups together, they have now the technologies, the people, and the operational excellence to further accelerate what has always been at the core of their project, which is innovation and growth. So yes, we're very pleased to remain involved and invested in the new chapter.

Unknown 1
48:52 - 48:56

Thank you. Charles, aren't you.

Arne Boye Nielsen
48:58 - 50:06

I've been super excited. It has been super exciting to see how excited the people, the ones that have known a little bit about this before the announcement today, how excited they are about the future and the opportunities that this brings to us. And I don't think it's a secret. You know, the level for critical mass in this industry is increasing year by year. And we have not been able to get to that level ourselves fast enough. And with this level now, with these two companies joining forces, we are truly reaching a strong foundation and a stable level where we can continue the growth path we have been on. And I'm very confident about the margin improvements as well. So I look forward to seeing; that's how I'm driven. Driven. I look forward to seeing how we engage the team, grow our market share, and improve our margins. Then it will be fantastic. 2019. Fantastic outcome. Yeah.

Unknown 1
50:07 - 50:09

Thank you Marc for finishing.

Dr. Marc Abitbol
50:09 - 51:13

Yeah. So, life is short, and I was always wondering what the next step for Visionix would be, and the cycle is long in our industry. And I think this is a unique opportunity to accelerate this process faster than any other alternative. And I am extremely excited and feel a strong emotion to know that I am going to participate in this second cycle. And it is not a given. I could have exited and forgotten it, but now I'm going to be part of another beginning of something which is really fantastic. And what about people? I can tell you ten times. I was thinking that in Finland, you would only find cold people. This is wrong. I found the warmest people I've met in this industry. And thank you very much for the wonderful guests you have and how you take care of me. Okay. Wow. Let's go.

Unknown 1
51:15 - 53:54

I think we finish up with that. Thank you, gentlemen. I'll let you take your seats, then I'll wrap up, and then we'll move to the Q&A. One more slide to go. Today this is a significant day for Revenio. It's a significant day for Visionix team. I think it's a significant day for our patients. Like Charles said. We are really improving as a joint company. We are expanding our reach in eye care services. So we are able to help more people to keep the wonderful world visible for all. Then secondly, this is a really good combination for our customers. So, we have a complete product portfolio in terms of the total addressable market. We are moving from 1 billion to 2.5 billion. Entering new segments that are growing faster than our previous 1 billion addressable market. Then, in terms of the team, in terms of all our stakeholders, we are really increasing the scale. We are increasing the scale in portfolio, we are increasing the scale in the channel. And that is beneficial for the Visionix team. It's beneficial for Revenio team. It's beneficial for all our partners. And then the last part is of course the shareholders. So I'm extremely happy to see the existing Visionix shareholders commit to the long-term growth story. And with this transaction, we are really accelerating the growth, and we are accelerating the value creation with these words. I think it's time for the Q&A. Robin, if you can come here, the plan for the Q&A is as follows. So we start with the live audience here, and let's see how many questions there are going to be. And then, of course, our online team is going to help us to ask the questions from the online participants. So there's going to be a big bunch of questions coming through there.

Robin Pulkkinen
53:55 - 53:55

Long list already.

Unknown 1
53:55 - 54:01

A long, long list. So bear with us. But.

Pierre Rosqvist
54:04 - 54:09

Thank you. I'm Pierre Rosqvist from DMV Carnegie. I also have a long list.

Unknown 1
54:09 - 54:10

Okay.

Pierre Rosqvist
54:11 - 54:39

I'll try to limit myself, but I'm really eager to hear more about this. Visionix. So, how has the growth journey looked? I saw from the press release that the company did not grow last year. So, what does the growth journey historically look like and what can you tell me about the profitability development of the company over the years?

Unknown 1
54:40 - 54:41

Should we?

Robin Pulkkinen
54:41 - 54:42

Maybe Marc?

Unknown 1
54:42 - 54:57

Yeah, maybe Dr. Marc, if you'd like to tell a bit about the history. If you. Yeah, you are visible on the webcast as well. So you can come into the middle if that's okay. Or I go in there.

Dr. Marc Abitbol
54:58 - 58:26

Okay, whatever you want. Okay, let's talk about the historical growth of Visionix. We had two very strong forms of compounding growth. Okay. External and organic growth. And indeed, 2023 and 2024 were more stable. We experienced very strong post-COVID growth, double the market's rate. I think we were around 10%. Just to give you a figure, in 2019, when Caravelle acquired a majority in Visionix, we were close to €90 million, and today we are at €144 million. So we had a strong rebound post-COVID. The second half of 2020 was the best at that time, and 2021 and 2022 also showed strong performance, but 2023 was flatter. So we had a historical trajectory where we grew. We had some plateaus and we continue to grow. To give a reference, in 2010, we were around €50 million. So you can see the progression, and part of it came from acquisitions and part from organic growth. I think we started in 2003 around €12 million. So, 2010 saw 52 million, 2019 was in the 80s, close to 90 million, and so on. So that has been the journey. In fact. As a startup company, it took us some time to find the market segment and the right product, which was unique in our market and gave us the growth potential. Regarding the profitability. So there are two factors that have impacted our profitability. And I will also describe the plan we have. First of all, we had an impact on manufacturing costs post-COVID. If you remember, there was quite a severe impact in the cost of components, etc. And that was the first one. The second one. We have been impacted by the currency because we have manufacturing in Israel, and the new Israeli shekel was at five shekels to a euro. Today it is 3.6. So, these manufacturing costs became relevant. So that's also impacted a bit of our profitability; as a consequence, in the middle of last year, we started a plan to recover this loss of profitability. We hired a consulting company called FSO, and we developed a very detailed plan in order to recover 4 to 5 points in our gross margin, which this plan is designed to achieve. This plan should start this year already to generate improvement in gross margin and be completed during 2027, and it is going to be part of the complete plan of the two companies. From our point of view, we are already executing, having reviewed our entire manufacturing portfolio and initiated the redesign of expensive parts with our suppliers. So now we are starting the execution of this plan. And this is not even in the very nice uplift that Jouni has presented to you.

Unknown 1
58:27 - 58:31

Thank you Mark. Hopefully that answered your question.

Pierre Rosqvist
58:31 - 58:48

Thank you. I'm just trying to do a quick calculation here. So, taking a reading from your answer. If you had an EBIT margin of 7% in 2025, then adding 4 to 5% to that would then represent the new level.

Unknown 1
58:48 - 59:31

I think now the guidance police jumps in. So we are going to give you the guidance of the combined company. Then later on, regarding profitability. What we are currently saying is that for sure the EBITDA is going to be improved, and by 2029, hitting towards 20-25% EBITDA levels above where we currently are; but we are going to have combined guidance, and the previous guidance is basically off. So we are going to guide the top line growth and profitability. Now. Reasonably soon. Sorry.

Pierre Rosqvist
59:32 - 59:33

Okay.

Unknown 1
59:33 - 59:33

Jump in.

Pierre Rosqvist
59:36 - 59:51

Then. With regards to OCT, that is something that you have been attracted to. And we have discussed that many times. How big a share of sales does OCT represent of Visionix today?

Robin Pulkkinen
59:54 - 59:58

So, do you have the exact number in mind? Marc. Yeah.

Dr. Marc Abitbol
59:58 - 59:59

It's about 30 million.

Robin Pulkkinen
60:01 - 60:02

30 million?

Pierre Rosqvist
60:03 - 60:04

30, 30.

Unknown 1
60:04 - 60:05

Yes.

Pierre Rosqvist
60:05 - 60:26

Okay. Thank you. Very good. Uh, then, uh. I'm sorry. I haven't had time yet to dig into all the details at Visionix website, but do you have any market shares to be disclosed? What is your position in the product market?

Unknown 1
60:26 - 60:40

So we come back to that one as well when we have a combined company. Sorry. So, as we sort out the combined company, we can discuss the market share. Alignment is still needed there.

Pierre Rosqvist
60:41 - 61:09

Okay, a final question. I have more to come. But regarding the market growth ambition rate. So you want to grow three times faster than the market. So you can just quantify based on all the product categories. What does that mean for revenue? Are we still talking about 9 to 12% annual growth? Is that three times faster than the market of the combined company?

Unknown 1
61:09 - 61:27

Yeah, I think that's a ballpark. Yes. So currently the market growth is between 3% to 4%. I think we have been the only one who has been able to grow together with Visionix, more or less. If we look. It's an interesting question how the market has been growing last year. But that's ballpark, right, Robin?

Robin Pulkkinen
61:27 - 61:28

Yeah.

Pierre Rosqvist
61:28 - 61:29

All right. Thank you.

Daniel from Danske Bank
61:32 - 62:01

All right. Thank you. It's Daniel from Danske Bank. Thank you for the presentation. I'll continue, still on the Visionix sellers, and maybe questions for the sellers and chairman. Can you disclose or clarify a bit what was the status of Visionix before this transaction? Has this company been for sale or is there an exit process ongoing? Can you clarify what was the status of Visionix before this?

Jouni Toijala
62:02 - 62:19

Can you hear me? Yeah. No, definitely not for sale. We've been having discussions for the past two years with Jouni. And definitely, we pushed back, if I may say. Yeah, yeah.

Unknown 1
62:20 - 62:23

Slightly, if I may say honestly speaking.

Jouni Toijala
62:23 - 62:47

We thought for a long time about joining forces, but we pushed back because we thought that we still had many things to do at Visionix. As Marc just mentioned. So no, they've just been very convincing to make us accelerate joining forces, but for sure it was not for sale.

Dr. Marc Abitbol
62:49 - 63:02

I think what has convinced us is one day we sat together. We sat together, if you remember, in Paris, and we looked at the combined portfolio, and we identified all the benefits, and every minute we said, 'Wow!'

Robin Pulkkinen
63:03 - 63:04

So the synergies.

Dr. Marc Abitbol
63:05 - 63:14

The synergy. And then I came back to Charles and I said, 'Charlie, let's talk now because there is a really amazing project here.'

Daniel from Danske Bank
63:15 - 63:33

All right. That's a good clarification. Maybe the next question on the synergies, then I guess you had some breakdown in the presentation clarifying between maybe top-line and cost synergies. Can you give us any rough estimates? Is it 50/50 or some other split?

Unknown 1
63:34 - 63:35

60/40.

Robin Pulkkinen
63:35 - 63:36

40 or.

Daniel from Danske Bank
63:36 - 64:05

Sixty-forty. So 60 for cost and 40 for top line. Yeah. All right, then I guess the final question on the different segments that you are now getting: What are the rough or the highest growth percentages that you are seeing in these new segments? Talking OCT, and all the new segments that you are having now.

Unknown 1
64:06 - 64:31

So based on the latest market study, of course, it might vary between the different studies, but for the OCT, it's roughly 44.5%. Between 4 and 5. Closer to five. Then I think on the multimodal side, the growth has been even even higher. So that's a good additional growth segment for us in the long run.

Daniel from Danske Bank
64:33 - 64:37

All right, I can stop here and maybe come back later.

Unknown 1
64:37 - 64:42

Okay. Thank you. Thank you. Johnny.

Johnny from Nordea
64:45 - 65:12

Yeah. Thanks. Johnny from Nordea. Maybe one question on the assembly or manufacturing of Visionix. Because as we know, Revenio doesn't have its own manufacturing. So, are you planning now to in-source more of Revenio's production to Visionix assembly sites? And secondly, how balanced is the manufacturing footprint geographically?

Unknown 1
65:13 - 66:05

So there are a couple of manufacturing plants currently. So, four in total. So two in-house, one joint venture in China. And then the OCT manufacturing is outside. And now we are starting to plan in coming quarters what we are going to do on the manufacturing assembly side. The plan is still open, but it's crystal clear that, as Marc said, on the manufacturing and assembly side, there are a lot of lean improvement activities now ongoing on the Visionix side. And we do the same all the time with our manufacturing partners, which are external. So the work is going to start in coming months and quarters.

Johnny from Nordea
66:06 - 66:07

Okay. Thanks.

Unknown 1
66:07 - 66:20

Thank you. The silence, but I think we have a really busy time. Really busy.

Unknown 2
66:20 - 66:30

Yeah. Maybe before we go here, I don't know if there's any questions on the lines that we could take this on live. Before we jump into the chat questions.

Operator
66:31 - 66:55

If you wish to ask a question, please dial star five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial star five again on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers.

Unknown 2
66:56 - 66:57

All right.

Unknown 1
66:57 - 66:59

Go to the iPad. iPad.

Unknown 2
66:59 - 67:14

Let's go to the iPad. So, sales related. I think this is a threefold question, but what will be the sales strategy of the combined entity? How are the sales synergies meant to materialize and how will the sales channels be optimized?

Unknown 1
67:15 - 69:10

That's a bit difficult question. Perhaps I cover a bit from the opportunity perspective, and the reason for this is that currently we don't have complete data. So, part of the sales data, regarding the detailed revenue, revenue split, cross-matching, etc. . Because of antitrust considerations, the detailed sales data remains in the clean room, and as a combined company, we will only gain access to both companies' detailed sales-related data after the closing. But, if I try to partly answer the question that was asked? So the USA will be a very significant opportunity for us. Visionix team goes direct, and then we are the top player in the USA when going forward with the fully blown holistic portfolio of the product. And we haven't been as Revenio before in all the big national accounts. So, this is going to be a path to enter these discussions. Then on the other geographies, extremely low-hanging fruit. In Spain, Visionix is already distributing our products. Then, I am really looking forward to starting discussions with the distributors to present the complete portfolio. I think we can achieve great things together with our distribution partners in Europe and APAC as well. But I think more to come on that one. Also, during the Capital Markets Day, when we get all the nitty-gritty details on the performance in every region, in every country, all the margin data, etc. .

Robin Pulkkinen
69:10 - 69:28

Also, they have direct channels to many countries in Europe, which we currently use distribution channels for. So we leave 40, 45% of the money on the table in every country currently. So it's not difficult to assume those will be some countries and areas we will be looking into quite quickly.

Unknown 2
69:30 - 69:41

Thank you. The next question on synergies: which synergies are the fastest to realize and which are the slowest? So referring to this 70% until 2027.

Robin Pulkkinen
69:42 - 69:49

The fastest is Spain. Because we close it, it's done. We eliminate certain transactions from there on.

Unknown 1
69:49 - 70:46

I would say top-line. Then perhaps the slowest. Let's see what we think about the ERP and so forth. On the sales side, for sure, there are lots of low-hanging fruits. Then perhaps the overall IT system integration. When it comes to the CRM and ERP systems, and so forth. So I think we have to get those details in good shape, but that might take a bit longer time. To sum up, the goal is between 2026 and 2027, and regarding the value creation and synergy EBITDA uplift of 20 million, 70% will be achieved by the end of 2027.

Unknown 2
70:49 - 71:01

Thank you. Next on brand, will you keep the Visionix brand or move directly to Revenio branding for consistency and not confusing end users and creating Marcom alignment?

Unknown 1
71:03 - 72:28

This is a more complicated topic. We haven't started much discussion on this one. So if we go really back, and now I even bring the Revenio brand into this discussion. So if we really go back to Revenio as a group name. So we used to have eight legal entities, I mean, Robin's reports 11 years ago, we had the LED signs, etc. . So that was the logic for Revenio. Then, after fine-tuning its portfolio to focus solely on tonometers, reducing its employee count from 1,000 to 30, and operating exclusively with tonometers, it proceeded to acquire CenterVue, then Ocular, then Retina. Now, we join forces with Visionix. So that starts to be such a big package that I think it's too early to say. We have to look at the overall branding, starting with Revenio Group as a brand, because it now causes confusion. So we have a brand as a Visionix brand. And for many shareholders, we have a Revenio brand. So we are coming back to this one. And luckily, we have here. Justin Evelynr, who is looking most probably at the branding also in the long run. So we have a good team to look into that one.

Unknown 2
72:30 - 72:45

Thank you. Then, a more finance-related question. There's a clear difference in EBITDA and EBIT for Visionix. So what does the D&A consist of? Is it capitalized R&D or PPA amortization?

Unknown 1
72:46 - 72:58

I think, sorry. Yeah yeah yeah sorry. But this is also linked to what Marc already partly answered. So, the post-Covid manufacturing issue and the currency are relevant. But do you want to comment on the PPA?

Robin Pulkkinen
72:59 - 73:03

No, it was regarding Visionix standalone numbers. I think so, yeah.

Unknown 1
73:03 - 73:06

Yeah. Okay. But I think Mark covered that one already.

Robin Pulkkinen
73:06 - 73:16

That was a bit. Yeah. Yeah. Basically, in Visionix's PNL, depreciation primarily stems from PPA amortization, not capitalized R&D.

Unknown 2
73:17 - 73:32

Yes. All right. And then there is a question on this revenue mix. Can we further elaborate on the mix between different brands and product areas and how much overlap there is in products?

Unknown 1
73:33 - 73:43

Not at this stage. So we come back to that one. And really the reason is that part of the things are still being processed in a clean room.

Unknown 2
73:44 - 73:54

Thank you. And a final question from the chat is: could you talk about the AI strategy of the combined company?

Unknown 1
73:56 - 75:18

Um, yes. Let's approach it this way. First, from the revenue perspective. And I think that applies also for Visionix Marc to correct me if I'm wrong. So this is a huge opportunity of bringing the algorithms and AI inside the devices, whether it is to improve the clinical decision-making or the overall experience and usability of the devices. Then the second thing on the AI front is, of course, what sits on the backend. So we have an Illume solution for that one, which covers the doctors, the Illume retina screening platform, and the AI. Then if we go for Visionix product offerings, then they have the data management platform, which is then utilizing the AI. So I think, more or less same strategy, same logic, and how this is going to go forward is that we form the portfolio strategy, we form the product strategy in the coming months to be communicated together with the AI plans during the CMD October November timeframe.

Unknown 2
75:20 - 75:25

Thank you. That was all of the questions for now. I don't know if there's more in the audience or do we?

Unknown 1
75:26 - 75:27

Thank you Marie.

Pierre Rosqvist
75:29 - 75:58

Thank you. It's Pierre from WDI again. I'm still curious. I would really appreciate if you would help me understand the product portfolio profitability in Visionix. So just looking at the EBIT margin of that business and compare it to you. So I tried to get a grasp on the quality of the products and the standing. So are there any loss-making parts in Visionix?

Unknown 1
75:59 - 75:59

No.

Pierre Rosqvist
76:02 - 76:19

And in terms of sales distribution, I think you showed a picture of it, but I can't recall how much sales came from OEM distribution, specifically for your products or Visionix. Did you show that?

Unknown 1
76:20 - 76:54

Yeah. We will come back to all these when they are clarified. What we currently have are the 25 numbers, and it follows a similar logic. We are currently determining how to report the combined company's numbers, as we did not provide specific breakdowns from the €109 million last year. How much was Tonometers? How much was Fundus imaging. How much was the perimeter part? So we come back to this one.

Pierre Rosqvist
76:54 - 77:06

P all right. Thank you. And with this new combination of Revenio and Visionix, who would you name as your main competitors?

Unknown 1
77:08 - 77:35

What would I say? Maybe Japan. I think I would say Nidec. Of course we have. Depending on the region, ultra-widefield, it's a choice, right? Optos. So more or less depending on the market. But I think now we are on the fully blown product portfolio. So that's a competitive package.

Pierre Rosqvist
77:36 - 77:37

All right. Thank you.

Unknown 1
77:37 - 77:38

Thank you, Pia.

Unknown 2
77:40 - 77:44

And it seems we have one question on the line. So should we take that.

Unknown 1
77:45 - 77:46

Yeah, we take that.

Operator
77:49 - 77:54

The next question comes from Nico Ruokangas from SEB. Please go ahead.

Nick Ruokangas
77:57 - 78:44

This is Nick from SEB. Thank you for the presentation. I have two questions and I'd like to start to discuss a bit more. Still on the sales synergies. So, could you discuss whether the sales synergies are more about selling OCT or other acquired products into Revenio's existing sales channels, or alternatively, selling Revenio products into Visionix's sales channels? And then I guess there are also some negative sales synergies as you have some overlapping products. So how big do you estimate those to be?

Unknown 1
78:46 - 80:01

So I think Nick. Hi. And thank you for calling in. So, it's a combination of many things, including those you mentioned. So we already have certain customers within our reach. And then of course, in the long run, we are able to offer a more comprehensive portfolio for that one. So that's the upselling and cross-selling aspect. The same applies for the Visionix team. Again, taking certain products from us, packaging, combining, and moving the product forward. And then, the significant part, of course, is that there are still certain customers who are not customers of ours or Visionix, but now we have a full-blown portfolio, big national accounts in the USA as an example. So now we are starting to be a major player with a full-blown turnkey product portfolio. So for sure, we are going to get new deals as well.

Nick Ruokangas
80:04 - 80:13

Okay, good. Sounds good. And then on the overlapping sales, will this have a negative impact compared to the pro forma?

Unknown 1
80:13 - 80:19

I know there's only one product VX 610. And that's a really tiny tiny one. So the answer is no.

Nick Ruokangas
80:22 - 80:25

All right. Great. Thank you. That's all for me.

Unknown 1
80:30 - 80:52

It seems that we are starting to come to an end. Thank you very much for your time. Thank you for your participation in the webcast and to all our audience. Have a great afternoon. Sunny afternoon. If you are in Helsinki and have a good afternoon, wherever you are. Thank you, thank you.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…